Advertisement

News

  • Novel obesity medications open door to new era in treatment of OSA

    Novel obesity medications open door to new era in treatment of OSA

    In December 2024, the FDA approved tirzepatide, a dual GIP and GLP-1 receptor agonist previously approved for type 2 diabetes and obesity, as the first prescription medication for adults with moderate to severe OSA and obesity.


  • COVID-19 immune patterns offer hope for future IPF treatment

    COVID-19 immune patterns offer hope for future IPF treatment

    Jose D. Herazo-Maya, MD, and colleagues are investigating a mechanism of T-cell suppression that may contribute to the development of a treatment for pulmonary fibrosis.


  • Understanding high-risk factors like PM2.5 in lung cancer

    Understanding high-risk factors like PM2.5 in lung cancer

    Renelle Myers, MD, FRCPC, discusses factors beyond tobacco use that clinicians should consider when screening for lung cancer, such as pollution exposure.


  • Study demonstrates viability of biologics for severe asthma, COPD exacerbations in eosinophilic inflammation

    Study demonstrates viability of biologics for severe asthma, COPD exacerbations in eosinophilic inflammation

    While larger studies are needed, Dharani K. Narendra, MD, FCCP, said the findings from the ABRA trial could be a game changer and reduce the need for glucocorticoids for some patients.


  • Growing evidence links perinatal exposures and childhood asthma risk

    Growing evidence links perinatal exposures and childhood asthma risk

    Research by Christian Rosas-Salazar, MD, MPH, is improving understanding of mechanisms at play from such exposures as antibiotics, RSV, tobacco smoke, and more.


  • Athletes require special considerations for everything from respiratory viruses to cardiovascular concerns

    Athletes require special considerations for everything from respiratory viruses to cardiovascular concerns

    Eli Friedman, MD, said that when treating athletes, clinicians must consider their unique needs and how their high activity levels may impact their health care journey.


  • Updates in ninth edition of TNM classification criteria allow for more precise lung cancer staging

    Updates in ninth edition of TNM classification criteria allow for more precise lung cancer staging

    Hisao Asamura, MD, said the changes are critical to clinical decision-making in the evolving thoracic oncology treatment landscape.


  • Exploring the evolving landscape in combination therapies for EGFR-mutated advanced NSCLC

    Exploring the evolving landscape in combination therapies for EGFR-mutated advanced NSCLC

    Susan Scott, MD, discussed the findings from the MARIPOSA and FLAURA2 trials and the next steps to identify who may benefit from which regimen.


  • FDA proposal would eliminate addicting power of cigarettes, other combustible tobacco products

    FDA proposal would eliminate addicting power of cigarettes, other combustible tobacco products

    While the rule could reduce smoking rates, Sven-Eric Jordt, PhD, said clinicians must remember that low-nicotine cigarettes still expose those who smoke to carcinogens.


  • Intersection of American Heart Month and Black History Month offers chance to highlight disparities in care

    Intersection of American Heart Month and Black History Month offers chance to highlight disparities in care

    Marcus St. John, MD, said health system-wide checklists can combat implicit bias and help ensure all patients receive appropriate care.